Juan Verdaguer Autonell
Grado: Doctor/a
973 702 210
joan.verdaguer(ELIMINAR)@udl.cat
Publicaciones
-
Carrillo, Jorge; Puertas, Maria Carmen; Planas, Raquel; Pastor, Xavier; Alba, Aurora; Stratmann, Thomas; Pujol-Borrell, Ricardo; Ampudia, Rosa Maria; Vives-Pi, Marta; Verdaguer, Joan
Anti-peripherin B lymphocytes are positively selected during diabetogenesis.
MOLECULAR IMMUNOLOGY 45 3152-3162. .
-
Alba, A.; Planas, R.; Clemente, X.; Carrillo, J.; Ampudia, R.; Puertas, M. -C.; Pastor, X.; Tolosa, E.; Pujol-Borrell, R.; Verdaguer, J.; Vives-Pi, M.
Natural killer cells are required for accelerated type 1 diabetes driven by interferon-beta.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY 151 467-475. .
-
Planas, R.; Carrillo, J.; Clemente, X.; Verdaguer, J.; Pajol-Borrell, R.; Vives-Pi, M.
Gene expression analysis by microarrays in a human pancreas at the onset of autoimmune diabetes
Acta diabetologica 44 41-41. .
-
Puertas, Maria Carmen; Carrillo, Jorge; Pastor, Xavier; Ampudia, Rosa Maria; Planas, Raquel; Alba, Aurora; Bruno, Roxana; Pujol-Borrell, Ricardo; Estanyol, Josep Maria; Vives-Pi, Marta; Verdaguer, Joan
Peripherin is a relevant neuroendocrine autoantigen recognized by islet-infiltrating B lymphocytes.
JOURNAL OF IMMUNOLOGY 178 6533-6539. .
-
Carmen Puertas, Maria; Carrillo, Jorge; Pastor, Xavier; Ampudia, Rosa Maria; Alba, Aurora; Planas, Raquel; Pujol-Borrell, Ricardo; Vives-Pi, Marta; Verdaguer, Joan
Phenotype and functional characteristics of islet-infiltrating B-cells suggest the existence of immune regulatory mechanisms in islet milieu.
Diabetes 56 940-949. .
-
Planas, R.; Alba, A.; Carrillo, J.; Puertas, M. C.; Ampudia, R.; Pastor, X.; Okamoto, H.; Takasawa, S.; Gurr, W.; Pujol-Borrell, R.; Verdaguer, J.; Vives-Pi, M.
Reg (regenerating) gene overexpression in islets from non-obese diabetic mice with accelerated diabetes: role of IFNbeta.
Diabetologia 49 2379-2387. .
-
Palomer, X; Calpe-Berdiel, L; Verdaguer, J; Carrillo, J; Pastor, X; Mauricio, D; Blanco-Vaca, F
Atorvastatin does not decrease or delay diabetes onset in two different mouse models of type 1 diabetes.
Diabetologia 48 1671-1673. .
-
Carrillo, J; Puertas, MC; Alba, A; Ampudia, RM; Pastor, X; Planas, R; Riutort, N; Alonso, N; Pujol-Borrell, R; Santamaria, P; Vives-Pi, M; Verdaguer, J
Islet-infiltrating B-cells in nonobese diabetic mice predominantly target nervous system elements.
Diabetes 54 69-77. .
-
Alba, A; Puertas, MC; Carrillo, J; Planas, R; Ampudia, R; Pastor, X; Bosch, F; Pujol-Borrell, R; Verdaguer, J; Vives-Pi, M
IFN beta accelerates autoimmune type 1 diabetes in nonobese diabetic mice and breaks the tolerance to beta cells in nondiabetes-prone mice.
JOURNAL OF IMMUNOLOGY 173 6667-6675. .
-
Yamanouchi, J; Verdaguer, J; Han, B; Amrani, A; Serra, P; Santamaria, P
Cross-priming of diabetogenic T cells dissociated from CTL-induced shedding of beta cell autoantigens.
JOURNAL OF IMMUNOLOGY 171 6900-6909. .
-
Serra, P; Amrani, A; Yamanouchi, J; Han, BY; Thiessen, S; Utsugi, T; Verdaguer, J; Santamaria, P
CD40 ligation releases immature dendritic cells from the control of regulatory CD4(+)CD25(+) T cells
Immunity 19 877-889. .
-
Yamanouchi, J; Verdaguer, J; Han, B; Amrani, A; Serra, P; Santamaria, P
Fas-dependent killing of beta cells by diabetogenic CD8+T lymphocytes in vivo requires a cognate interaction between effector lymphocytes and their targets
Diabetes 51 90-90. .
Proyectos
- Estudio del impacto generado por modificaciones en la microbiota intestinal sobre la actividad del sistema inmune en el modelo murino NOD de diabetes autoinmune.
- OncoNeoVac, un nuevo enfoque inmunoterapéutico para el tratamiento del melanoma.
- INVESTIGO 2022: Grup de Recerca en Immunologia i Metabolisme (GRIM)
- Modelación de la microbiota intestinal en las etapas iniciales del desarrollo de la diabetes autoinmune en el ratón NOD, modelo de la diabetes tipo 1 humana.
- Estudi de l'efecte adjuvant de DIF-P en una vacuna antigripal
- Linfocitos T y B anti-periferina y anti-cromogranina T and B lymphocyte durante el desarrollo de la Diabetes Mellitus Tipo 1 (APACT1D)
- Linfocitos B y T autoreactivos en la diabetes del tipo 1: Análisis funcional y desarrollo de estrategias de tratamiento (BATINT1D)
- CARACTERIZACIÓN DE LA RESPUESTA DE LINFOCITOS B AUTOREACTIVOS CONTRA UN NUEVO AUTOANTIGENO DE 90 KDA ESPECIFICO DE CELULAS BETA PANCREATICAS DURANTE EL DESARROLLO DE LA DIABETES TIPO 1
- IDENTIFICACIO DEL NOU AUTOANTIGEN ICA85 I CARACTERITZACIO DE LA RESPOSTA AUTOINMUNITARIA CONTRA AQUEST EN PACIENTS AMB DIABETIS TIPUS 1